November 12, 2008 event

November 12, 2008 Innovation Series

Neuroscience Drug Discovery and Development:

The Route to Disease-Modifying Therapies

Program Description:

Disorders of the brain, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease and psychiatric diseases such as schizophrenia and depression, pose some of the hardest challenges for the biopharmaceutical industry. The disease burden from brain disorders is enormous, and the commercial potential is correspondingly attractive to industry and its investors. However, complex pathophysiology, poor preclinical models, a lack of reliable biomarkers and expensive clinical trials all impede development of new therapies. Join us for a discussion of how the biopharmaceutical industry is addressing these challenges, with guest speakers from the cutting edge of neuroscience drug discovery.